Delivery Order SPE2DB22D1052-SPE2DB25FU9UT
- Not listed
- The Defense Logistics Agency awarded a $25,044.82 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $34,374.97 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count units) on August 5, 2025, with completion targeted for August 6, 2025. This firm fixed price, non-set-aside contract represents a routine pharmaceutical procurement executed under competitive procedures. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical supplier for federal...
- The Defense Logistics Agency awarded a delivery order valued at $1,617.24 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count supply) on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $2,729.22 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (30-count supply). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 1, 2025, and represents a competitively awarded transaction under AmerisourceBergen's broader pharmaceutical supply relationships with the federal government. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units) under a firm fixed-price contract valued at $8,276.16. The award was made on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, non-set-aside delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a routine pharmaceutical procurement...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $29,045.67 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count supply) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a primary...
- The Defense Logistics Agency awarded a delivery order valued at $9,851.48 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units). This firm fixed-price, non-set-aside delivery order was awarded on August 8, 2025, with an ultimate completion date of August 11, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,159.46, is for the supply of Myrbetriq ER 50 mg tablets. The contract is a firm-fixed-price delivery order with a period of performance through March 16, 2023. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
- This is a $11,857.03 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Myrbetriq ER 25 mg tablets, with a performance period through May 8, 2023. This award is part of AmerisourceBergen's broader $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,881.13 firm fixed-price delivery order is for the supply of the drug Myrbetriq ER 50 mg tablets. The contract has a completion date of December 27, 2024. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- SPE2DB22D1052Indefinite Delivery Contract
- SPE2DB22D1052-SPE2DB25FU9UTDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count supply) under a firm fixed price contract valued at $8,425.09. This award was competitively procured with no set-aside designation and is scheduled for completion by August 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through DLA's Medical Supply Chain. This delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical commodities to support military healthcare programs globally. The Myrbetriq supply falls within the broader pharmaceutical portfolio managed under this IDC, which encompasses specialty medications, brand-name and generic drugs, and other medical supplies across multiple therapeutic domains for customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.4k | 8/8/25 |